Egrifta Articles
Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA
27 June 2012
Theratechnologies to quit COPD program
8 December 2011
US FDA approves Merck KGaA Egrifta to treat lipodystrophy in HIV patients and development plan for Bionovo’s Menerba
11 November 2010
Showing 1-3 of 3 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
